TLR7 and basal cell carcinoma: The TLR7 agonist imiquimod, approved by the FDA for squamous and basal cell carcinoma via topical application, and the TLR7/8 agonist resiquimod are also being tested in GB, but less so than Hiltonol (Table 1, Figure 3).